Acelyrin
![Acelyrin, clinical trial data, inflammatory diseases, failed trials, ulcerative colitis, phase 3 trial, IPO, stock price](https://pharmtales.com/wp-content/uploads/2023/09/Acelyrins-lead-drug-flops-in-phase-3-trial-wiping-out-half-of-its-market-value.jpg)
Acelyrin’s lead drug flops in phase 3 trial, wiping out half of its market value
Anika Sharma
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...